Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Santoni, M; Massari, F; Myint, ZW; Iacovelli, R; Pichler, M; Basso, U; Kopecky, J; Kucharz, J; Buti, S; Rizzo, M; Galli, L; Buettner, T; De Giorgi, U; Kanesvaran, R; Fiala, O; Grande, E; Zucali, PA; Fornarini, G; Bourlon, MT; Scagliarini, S; Molina-Cerrillo, J; Aurilio, G; Matrana, MR; Pichler, R; Cattrini, C; Buechler, T; Seront, E; Calabro, F; Pinto, A; Berardi, R; Zgura, A; Mammone, G; Ansari, J; Atzori, F; Chiari, R; Bamias, A; Caffo, O; Procopio, G; Bassanelli, M; Merler, S; Messina, C; Kueronya, Z; Mosca, A; Bhuva, D; Vau, N; Incorvaia, L; Rebuzzi, SE; Roviello, G; Zabalza, IO; Rizzo, A; Mollica, V; Sorgentoni, G; Monteiro, FSM; Montironi, R; Battelli, N; Porta, C.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
TARGET ONCOL. 2023;
Doi: 10.1007/s11523-023-00978-2
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.